1.82
+2.25%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lexicon Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Lexicon Pharmaceuticals is based in The Woodlands, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LXRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $49.8m and a net loss of $50.3m. At that date it held total assets of $185.0m and shareholders' equity of $107.5m.
The FDA has separately provided feedback that a third-party-funded, investigator-initiated study of sotagliflozin appears to be of adequate design and employs sufficient data collection methods to provide viable evidence of the incidence of diabetic ketoacidosis, or DKA, with adequate safety data, prior to its completion, to support review of a resubmission of the NDA. We are preparing to potentially resubmit the NDA for ZYNQUISTA in type 1 diabetes if supported by patient exposure and safety data from such study.
Sotagliflozin, LX9851 and compounds from a number of additional drug programs originated from our own internal drug discovery efforts and pilavapadin originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb. Our efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.
Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Apr 2000
- Employees
- 81
- Website
- lexpharma.com ↗
- Head office
- 2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX, 77381
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Raymond DebbaneIndependent Chairman of the Board$217,051
- Mr. Michael ExtonChief Executive Officer, Director, since 2024$2.8m
- Mr. Scott CoianteSenior Vice President, Chief Financial Officer
- Dr. Alan MainExecutive Vice President - Innovation and Chemical Sciences$1.4m
- Mr. Brian CrumSenior Vice President, General Counsel$1.4m
- Ms. Wendy McdermottSenior Vice President of Human Resources
- Mr. Brian CorriganSenior Vice President - Regulatory and Quality Assurance
- Ms. Lisa DefrancescoSenior Vice President - Investor Relations and Corporate Communications
- Dr. Craig GranowitzSenior Vice President, Chief Medical Officer$1.6m
- Ms. Kristen AlexanderVice President - Finance and Accounting$613,245
- Mr. Philippe AmouyalIndependent Director$197,051
- Dr. Samuel BarkerIndependent Director, since 2000$209,551
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 58
- Social
- 99
- Governance
- 11
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lexicon Pharmaceuticals Inc has a strong portfolio of proprietary drug candidates, which gives them a competitive edge in the pharmaceutical industry.
- The company has a highly experienced and knowledgeable management team, allowing them to make strategic decisions and navigate complex regulatory processes effectively.
- Lexicon Pharmaceuticals Inc has a strong financial position, with a solid cash flow and manageable debt levels, enabling them to invest in research and development and pursue growth opportunities.
Weaknesses
- The company is highly reliant on a small number of drug candidates in their pipeline, which poses a risk if any of them fail to gain regulatory approval or face significant setbacks.
- Lexicon Pharmaceuticals Inc faces intense competition from both large pharmaceutical companies with significant resources and smaller biotech firms specialized in the same therapeutic areas.
- The company has limited marketing and distribution capabilities, which may hinder its ability to effectively commercialize and launch new products.
Opportunities
- The increasing global demand for innovative drugs presents an opportunity for Lexicon Pharmaceuticals Inc to expand its market presence and generate higher revenues.
- Collaboration and partnership agreements with larger pharmaceutical companies can provide access to additional resources, expertise, and distribution channels.
- Advancements in technology and genetic research open up possibilities for the development of personalized medicine, which presents a potential area for Lexicon Pharmaceuticals Inc to explore and capitalize on.
Threats
- Uncertainties and challenges in the regulatory environment can delay or prevent the approval and commercialization of Lexicon Pharmaceuticals Inc's drug candidates, impacting their revenue potential.
- The pharmaceutical industry is subject to rapid technological advancements and evolving market trends, which may require the company to continually adjust its strategies and offerings to remain competitive.
- Growing concerns about healthcare costs and pricing pressures from payers and regulatory bodies could impact the pricing and profitability of Lexicon Pharmaceuticals Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.